GPC
22
-3
INTU
47
4
ITW
61
2
RCL
77
-6
GIS
40
3
AVB
42
-3
MOS
42
2
NUE
50
2
ZTS
36
7
STI
40
-26
SWK
64
3
GLW
52
2
VRTX
43
-4
EQIX
57
-3
FITB
52
-4
MCD
54
4
NAVI
27
-3
CMG
63
9
STX
50
-2
FMC
50
-3
GPC
22
-3
INTU
47
4
ITW
61
2
RCL
77
-6
GIS
40
3
AVB
42
-3
MOS
42
2
NUE
50
2
ZTS
36
7
STI
40
-26
SWK
64
3
GLW
52
2
VRTX
43
-4
EQIX
57
-3
FITB
52
-4
MCD
54
4
NAVI
27
-3
CMG
63
9
STX
50
-2
FMC
50
-3
Financhill
Back

Grace Therapeutics 10K Form

Sell
39

GRCE
Grace Therapeutics

Last Price:
3.08
Seasonality Move:
7.4%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GRCE News And Ratings

See the #1 stock for the next 7 days that we like better than GRCE

GRCE Financial Statistics

Sales & Book Value

Annual Sales: $196K
Cash Flow: $-3.6M
Price / Cash Flow: 0
Annual Sales: $5.85
Price / Book: 0.54

Profitability

EPS (TTM): -1.42460
Net Income (TTM): $-11.45M
Gross Margin: $120K
Return on Equity: 0%
Return on Assets: 0%

Grace Therapeutics Earnings Forecast

Key Grace Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 1 years for GRCE is 61.22%.
  • The Selling, General & Administrative Expenses for GRCE have been equal to 3,395.41% of Gross Profit Margin.
  • Per Share Earnings over the last 4 years have been positive in 2 years.

Grace Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: GRCE
Website: acastipharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

GRCE Technical Analysis vs Fundamental Analysis

Sell
39
Grace Therapeutics (GRCE) is a Sell

Is Grace Therapeutics a Buy or a Sell?